|
On (b)(6) 2026, information was received from a manufacturer representative and patient regarding a trial patient who was using an external neurostimulator (ens) for urgency frequency and urge incontinence.It was reported that the trial was initiated on (b)(6)2026.It was reported that yesterday they started to have a presumed potential allergic reaction.The caller was not with the patient at the time of the call, but stated the patient called them last night and reported the issue.Agent sent the caller the spec sheets for the lead and extension to caller.The patient (pt) to follow up with managing healthcare provider (hcp).Additional information was received from the patient on (b)(6).The patient stated that they had a rash ever since the procedure.It was unknown if the issue was resolved.On (b)(6) 2026, additional information was received from the patient.It was reported that they were itchy and they had papular rash along their lower back and lead insertion site.They removed the lead and percutaneous extension.The issue was resolved.
|
|
Continuation of d10: product id 978b128 lot# unknown.Implanted: (b)(6) 2026 explanted: (b)(6) 2026.Product type lead product id 3560022 lot# va3bvy9.Implanted: (b)(6) 2026.Explanted: (b)(6) 2026.Product type extension section d information references the main component of the system.Other relevant device(s) are: product id: 978b128, serial/lot #: unknown.Product id: 3560022, serial/lot #: (b)(6), ubd: 18-aug-2028, udi#: (b)(4).Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|